Literature DB >> 26707129

Sex Dimorphism Profile of Alzheimer's Disease-Type Pathologies in an APP/PS1 Mouse Model.

Shu-Sheng Jiao1, Xian-Le Bu1, Yu-Hui Liu1, Chi Zhu1, Qing-Hua Wang1, Lin-Lin Shen1, Cheng-Hui Liu1, Ye-Ran Wang1, Xiu-Qing Yao1, Yan-Jiang Wang2.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia among the elderly, characterized by parenchymal and vascular beta-amyloid (Aβ) burden, tau pathology, neuroinflammation, and loss of neurons and synapses. There is a clear sex difference in the prevalence of AD. However, sex differences in AD-type pathologies have not been systematically documented. Applying 12-month-old female and male APP/PS1 mice as a model, we investigated the sex dimorphism in these major pathological indices. Compared with male APP/PS1 mice, the females exhibited higher parenchymal Aβ burdens, with the sex difference in hippocampus being the most significant. Female APP/PS1 mice had more severe cerebral amyloid angiopathy and subsequent microhemorrhage. In addition, female APP/PS1 mice also showed higher levels of phosphorylated tau and proinflammatory cytokines, more severe astrocytosis and microgliosis, and greater neuronal and synaptic degenerations. The present study systematically described a sex dimorphism in AD-type pathologic indices, suggesting that gender should be taken into account in designing studies involving these pathological indices and when interpreting the relevant findings in those studies.

Entities:  

Keywords:  Alzheimer’s disease; Beta-amyloid; Cerebral amyloid angiopathy; Loss of neurons and synapses; Neuroinflammation; Sex dimorphism; Tau pathology

Mesh:

Substances:

Year:  2015        PMID: 26707129     DOI: 10.1007/s12640-015-9589-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  44 in total

1.  1998 Curt P. Richter Award. The effect of hormone replacement therapy on cognitive function in elderly women.

Authors:  E Hogervorst; M Boshuisen; W Riedel; C Willeken; J Jolles
Journal:  Psychoneuroendocrinology       Date:  1999-01       Impact factor: 4.905

2.  Effects of sex hormones on Alzheimer's disease-associated β-amyloid oligomer formation in vitro.

Authors:  Akiyoshi Morinaga; Kenjiro Ono; Junichi Takasaki; Tokuhei Ikeda; Mie Hirohata; Masahito Yamada
Journal:  Exp Neurol       Date:  2011-01-31       Impact factor: 5.330

Review 3.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 4.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Authors:  Eric Karran; Marc Mercken; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2011-08-19       Impact factor: 84.694

Review 5.  Oestrogen replacement therapy and Alzheimer's disease.

Authors:  A Paganini-Hill
Journal:  Br J Obstet Gynaecol       Date:  1996-05

6.  Is the risk of developing Alzheimer's disease greater for women than for men?

Authors:  L E Hebert; P A Scherr; J J McCann; L A Beckett; D A Evans
Journal:  Am J Epidemiol       Date:  2001-01-15       Impact factor: 4.897

Review 7.  Gender, sex steroid hormones, and Alzheimer's disease.

Authors:  Rebekah S Vest; Christian J Pike
Journal:  Horm Behav       Date:  2012-04-19       Impact factor: 3.587

Review 8.  A comprehensive view of sex-specific issues related to cardiovascular disease.

Authors:  Louise Pilote; Kaberi Dasgupta; Veena Guru; Karin H Humphries; Jennifer McGrath; Colleen Norris; Doreen Rabi; Johanne Tremblay; Arsham Alamian; Tracie Barnett; Jafna Cox; William Amin Ghali; Sherry Grace; Pavel Hamet; Teresa Ho; Susan Kirkland; Marie Lambert; Danielle Libersan; Jennifer O'Loughlin; Gilles Paradis; Milan Petrovich; Vicky Tagalakis
Journal:  CMAJ       Date:  2007-03-13       Impact factor: 8.262

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.

Authors:  Suzanne E Hickman; Elizabeth K Allison; Joseph El Khoury
Journal:  J Neurosci       Date:  2008-08-13       Impact factor: 6.167

View more
  33 in total

1.  Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Jun-Ting Yang; Zhao-Jun Wang; Hong-Yan Cai; Li Yuan; Meng-Ming Hu; Mei-Na Wu; Jin-Shun Qi
Journal:  Neurosci Bull       Date:  2018-08-11       Impact factor: 5.203

2.  Gender differences of neuropsychological profiles in cognitively normal older people without amyloid pathology.

Authors:  Jie Zhang; Wenjun Zhou; Lijun Wang; Xiangyang Zhang
Journal:  Compr Psychiatry       Date:  2017-03-01       Impact factor: 3.735

3.  Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model.

Authors:  Héctor M Estévez-Silva; Germán Cuesto; Ninovska Romero; José Miguel Brito-Armas; Abraham Acevedo-Arozena; Ángel Acebes; Daniel J Marcellino
Journal:  Neurotherapeutics       Date:  2022-08-02       Impact factor: 6.088

4.  Naturally-Occurring Antibodies Against Bim are Decreased in Alzheimer's Disease and Attenuate AD-type Pathology in a Mouse Model.

Authors:  Jie-Ming Jian; Dong-Yu Fan; Ding-Yuan Tian; Yuan Cheng; Pu-Yang Sun; Cheng-Rong Tan; Gui-Hua Zeng; Chen-Yang He; Ye-Ran Wang; Jie Zhu; Xiu-Qing Yao; Yan-Jiang Wang; Yu-Hui Liu
Journal:  Neurosci Bull       Date:  2022-05-15       Impact factor: 5.271

5.  Early changes in synaptic and intrinsic properties of dentate gyrus granule cells in a mouse model of Alzheimer's disease neuropathology and atypical effects of the cholinergic antagonist atropine.

Authors:  David Alcantara-Gonzalez; Elissavet Chartampila; Chiara Criscuolo; Helen E Scharfman
Journal:  Neurobiol Dis       Date:  2021-01-20       Impact factor: 5.996

6.  The detrimental effects of APOE4 on risk for Alzheimer's disease may result from altered dendritic spine density, synaptic proteins, and estrogen receptor alpha.

Authors:  Lisa R Taxier; Sarah M Philippi; Jason M York; Mary Jo LaDu; Karyn M Frick
Journal:  Neurobiol Aging       Date:  2021-12-24       Impact factor: 4.673

7.  Sex differences in the IntelliCage and the Morris water maze in the APP/PS1 mouse model of amyloidosis.

Authors:  Marc A Mifflin; Wendy Winslow; Likith Surendra; Savannah Tallino; Austin Vural; Ramon Velazquez
Journal:  Neurobiol Aging       Date:  2021-01-23       Impact factor: 4.673

Review 8.  Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.

Authors:  Tamar Smit; Natasja A C Deshayes; David R Borchelt; Willem Kamphuis; Jinte Middeldorp; Elly M Hol
Journal:  Glia       Date:  2021-02-25       Impact factor: 7.452

9.  Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APPswe/PS1dE9 mice.

Authors:  Miren Ettcheto; Elena Sánchez-Lopez; Amanda Cano; Marina Carrasco; Katherine Herrera; Patricia R Manzine; Triana Espinosa-Jimenez; Oriol Busquets; Ester Verdaguer; Jordi Olloquequi; Carme Auladell; Jaume Folch; Antoni Camins
Journal:  Cell Biosci       Date:  2021-07-22       Impact factor: 7.133

10.  Q134R: Small chemical compound with NFAT inhibitory properties improves behavioral performance and synapse function in mouse models of amyloid pathology.

Authors:  Pradoldej Sompol; Jenna L Gollihue; Susan D Kraner; Irina A Artiushin; Ryan A Cloyd; Emad A Chishti; Shon A Koren; Grant K Nation; Jose F Abisambra; Orsolya Huzian; Lajos I Nagy; Miklos Santha; Laszlo Hackler; Laszlo G Puskas; Christopher M Norris
Journal:  Aging Cell       Date:  2021-06-12       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.